Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494998 | 0.98 | ALDH1A1 (0.49) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL7516017 | 0.93 | — | — | |
| SCHEMBL7508338 | 0.88 | — | — | |
| SCHEMBL7253708 | 0.84 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2AADRB2 | |
| SCHEMBL21343095 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL1966553 | 0.83 | ALDH1A1 (0.45) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL205737 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL8845363 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL10099631 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CES2CES1SMN1; SMN2MEN1 | |
| SCHEMBL30688256 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CES2CES1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| CN-109608436-A | Substituted Methylformyl reagent and the method for improving compound physical chemistry and/or pharmacokinetic property using the reagent | 斯法尔制药私人有限公司 | 2019-04-12 | — | — | CN | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| CN-103607888-A | Substituted methyl formyl reagents and methods of using the same to improve physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PRIVATE LTD | 2014-02-26 | — | — | CN | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4707284-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-5733924-A | BACTERICIDES AND ANTITUMOR AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| CN-1163616-A | DC107 derivatives | KYOWA HAKKO KOGYO KK (JP) | 1997-10-29 | — | — | CN | disclosed |
| EP-0786462-A1 | DC107 DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| US-4456465-A | HERBICIDES | ZOECON CORPORATION (US) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | ALDH1A1 524/4885CES2 399/4885CES1 511/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | ALDH1A1 1607/4885CES2 1409/4885CES1 3060/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | ALDH1A1 2478/4885CES2 660/4885CES1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.